Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant
immunotherapy with chemotherapy followed by esophagectomy to determine whether additional
adjuvant therapy is associated with improved survival outcomes.